Choice of Unmanipulated T Cell Replete Graft for Haploidentical Stem Cell Transplant and Posttransplant Cyclophosphamide in Hematologic Malignancies in Adults: Peripheral Blood or Bone Marrow-Review of Published Literature

Overview

Journal Adv Hematol

Publisher Wiley

Specialty Hematology

Date 2016 Apr 28

PMID 27118973

Citations 5

Authors

Shatha Farhan

Edward Peres

Nalini Janakiraman

Affiliations

Soon will be listed here.

Abstract

Allogeneic hematopoietic stem cell transplantation (SCT) is often the only curative option for many patients with malignant and benign hematological stem cell disorders. However, some issues are still of concern regarding finding a donor like shrinking family sizes in many societies, underrepresentation of the ethnic minorities in the registries, genetic variability for some races, and significant delays in obtaining stem cells after starting the search. So there is a considerable need to develop alternate donor stem cell sources. The rapid and near universal availability of the haploidentical donor is an advantage of the haploidentical SCT and an opportunity that is being explored currently in many centers especially using T cell replete graft and posttransplant cyclophosphamide. This is probably because it does not require expertise in graft manipulation and because of the lower costs. However, there are still lots of unanswered questions, like the effect of use of bone marrow versus peripheral blood as the source of stem cells on graft-versus-host disease, graft versus tumor, overall survival, immune reconstitution, and quality of life. Here we review the available publications on bone marrow and peripheral blood experience in the haploidentical SCT setting.

Citing Articles

Is Post-Transplant Cyclophosphamide the New Methotrexate?.

Mussetti A, Paviglianiti A, Parody R, Sureda A J Clin Med. 2021; 10(16).

PMID: 34441843 PMC: 8397193. DOI: 10.3390/jcm10163548.

Peripheral Blood Stem Cell Mobilization in Healthy Donors by Granulocyte Colony-Stimulating Factor Causes Preferential Mobilization of Lymphocyte Subsets.

Melve G, Ersvaer E, Eide G, Kristoffersen E, Bruserud O Front Immunol. 2018; 9:845.

PMID: 29770133 PMC: 5941969. DOI: 10.3389/fimmu.2018.00845.

Impact on early outcomes and immune reconstitution of high-dose post-transplant cyclophosphamide vs anti-thymocyte globulin after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation.

Retiere C, Willem C, Guillaume T, Vie H, Gautreau-Rolland L, Scotet E Oncotarget. 2018; 9(14):11451-11464.

PMID: 29545911 PMC: 5837739. DOI: 10.18632/oncotarget.24328.

Immune tolerance induction by nonmyeloablative haploidentical HSCT combining T-cell depletion and posttransplant cyclophosphamide.

Aversa F, Bachar-Lustig E, Or-Geva N, Prezioso L, Bonomini S, Manfra I Blood Adv. 2018; 1(24):2166-2175.

PMID: 29296864 PMC: 5737124. DOI: 10.1182/bloodadvances.2017009423.

Single-agent GvHD prophylaxis with tacrolimus after post-transplant high-dose cyclophosphamide is a valid option for haploidentical transplantation in adults with hematological malignancies.

Esquirol A, Pascual M, Ortiz M, Pinana J, Ferra C, Garcia Cadenas I Bone Marrow Transplant. 2017; 52(9):1273-1279.

PMID: 28604667 DOI: 10.1038/bmt.2017.111.

References

BERENBAUM M, BROWN I . PROLONGATION OF HOMOGRAFT SURVIVAL IN MICE WITH SINGLE DOSES OF CYCLOPHOSPHAMIDE. Nature. 1963; 200:84. DOI: 10.1038/200084a0. View

Pidala J, Kim J, Schell M, Lee S, Hillgruber R, Nye V . Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization. Bone Marrow Transplant. 2012; 48(3):346-50. PMC: 4500122. DOI: 10.1038/bmt.2012.150. View

Lu D, Dong L, Wu T, Huang X, Zhang M, Han W . Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2005; 107(8):3065-73. DOI: 10.1182/blood-2005-05-2146. View

Wang Y, Liu Q, Xu L, Liu K, Zhang X, Ma X . Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood. 2015; 125(25):3956-62. DOI: 10.1182/blood-2015-02-627786. View

Castagna L, Bramanti S, Furst S, Giordano L, Crocchiolo R, Sarina B . Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas. Bone Marrow Transplant. 2014; 49(12):1475-80. DOI: 10.1038/bmt.2014.197. View

Anasetti C, Logan B, Lee S, Waller E, Weisdorf D, Wingard J . Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012; 367(16):1487-96. PMC: 3816375. DOI: 10.1056/NEJMoa1203517. View

Switzer G, Bruce J, Myaskovsky L, DiMartini A, Shellmer D, Confer D . Race and ethnicity in decisions about unrelated hematopoietic stem cell donation. Blood. 2012; 121(8):1469-76. PMC: 3578960. DOI: 10.1182/blood-2012-06-437343. View

Castagna L, Crocchiolo R, Furst S, Bramanti S, El Cheikh J, Sarina B . Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant. 2014; 20(5):724-9. DOI: 10.1016/j.bbmt.2014.02.001. View

Kawase T, Morishima Y, Matsuo K, Kashiwase K, Inoko H, Saji H . High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood. 2007; 110(7):2235-41. DOI: 10.1182/blood-2007-02-072405. View

10.

Storb R, Yu C, Wagner J, Deeg H, Nash R, Kiem H . Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1997; 89(8):3048-54. View

11.

Jones R, Barber J, Vala M, Collector M, Kaufmann S, Ludeman S . Assessment of aldehyde dehydrogenase in viable cells. Blood. 1995; 85(10):2742-6. View

12.

Luznik L, Jalla S, Engstrom L, Iannone R, Fuchs E . Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001; 98(12):3456-64. DOI: 10.1182/blood.v98.12.3456. View

13.

Bashey A, Zhang X, Sizemore C, Manion K, Brown S, Holland H . T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor.... J Clin Oncol. 2013; 31(10):1310-6. DOI: 10.1200/JCO.2012.44.3523. View

14.

Nishimura Y, Mayumi H, Tomita Y, Eto M, Maeda T, Nomoto K . Recombinant human granulocyte colony-stimulating factor improves the compromised state of recipient mice without affecting the induction of specific tolerance in the cyclophosphamide-induced tolerance system. J Immunol. 1991; 146(8):2639-47. View

15.

McCurdy S, Fuchs E . Comparable Outcomes for Hematologic Malignancies after HLA-Haploidentical Transplantation with Posttransplantation Cyclophosphamide and HLA-Matched Transplantation. Adv Hematol. 2015; 2015:431923. PMC: 4680052. DOI: 10.1155/2015/431923. View

16.

Chen X, Gao L, Zhang X, Gao L, Zhang C, Kong P . HLA-haploidentical blood and bone marrow transplantation with anti-thymocyte globulin: long-term comparison with HLA-identical sibling transplantation. Blood Cells Mol Dis. 2009; 43(1):98-104. DOI: 10.1016/j.bcmd.2009.02.005. View

17.

Solomon S, Sizemore C, Sanacore M, Zhang X, Brown S, Holland H . Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors. Biol Blood Marrow Transplant. 2015; 21(7):1299-307. DOI: 10.1016/j.bbmt.2015.03.003. View

18.

Eto M, Yanaga K, Nishimura Y, Maeda T, Nomoto K . Interference with cyclophosphamide-induced skin allograft tolerance by cyclosporin A. J Immunol. 1992; 149(8):2668-74. View

19.

McCurdy S, Kanakry J, Showel M, Tsai H, Bolanos-Meade J, Rosner G . Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015; 125(19):3024-31. PMC: 4424420. DOI: 10.1182/blood-2015-01-623991. View

20.

Raj K, Pagliuca A, Bradstock K, Noriega V, Potter V, Streetly M . Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant. 2014; 20(6):890-5. PMC: 4451937. DOI: 10.1016/j.bbmt.2014.03.003. View